MEDICAL FACILITIES CORP (DR.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:DR - CA58457V5036 - Common Stock
15.87 CAD
+0.27 (+1.73%)
Taking everything into account, DR scores 7 out of 10 in our fundamental rating. DR was compared to 13 industry peers in the Health Care Providers & Services industry. DR gets an excellent profitability rating and is at the same time showing great financial health properties. DR is valued quite cheap, but it does not seem to be growing. With these ratings, DR could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
DR had positive earnings in the past year.
In the past year DR had a positive cash flow from operations.
DR had positive earnings in 4 of the past 5 years.
In the past 5 years DR always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of DR (30.18%) is better than 100.00% of its industry peers.
DR has a better Return On Equity (94.43%) than 100.00% of its industry peers.
DR has a Return On Invested Capital of 15.42%. This is amongst the best in the industry. DR outperforms 92.31% of its industry peers.
The Average Return On Invested Capital over the past 3 years for DR is significantly above the industry average of 7.27%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.18% | ||
| ROE | 94.43% | ||
| ROIC | 15.42% |
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
1.3 Margins
With an excellent Profit Margin value of 31.60%, DR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Profit Margin of DR has grown nicely.
DR's Operating Margin of 15.59% is amongst the best of the industry. DR outperforms 100.00% of its industry peers.
DR's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 63.75%, DR belongs to the top of the industry, outperforming 92.31% of the companies in the same industry.
In the last couple of years the Gross Margin of DR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.59% | ||
| PM (TTM) | 31.6% | ||
| GM | 63.75% |
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), DR is creating value.
DR has less shares outstanding than it did 1 year ago.
The number of shares outstanding for DR has been reduced compared to 5 years ago.
The debt/assets ratio for DR has been reduced compared to a year ago.
2.2 Solvency
DR has an Altman-Z score of 1.37. This is a bad value and indicates that DR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of DR (1.37) is better than 69.23% of its industry peers.
The Debt to FCF ratio of DR is 2.05, which is a good value as it means it would take DR, 2.05 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of DR (2.05) is better than 92.31% of its industry peers.
DR has a Debt/Equity ratio of 1.02. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of DR (1.02) is comparable to the rest of the industry.
Although DR does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.02 | ||
| Debt/FCF | 2.05 | ||
| Altman-Z | 1.37 |
ROIC/WACC1.79
WACC8.63%
2.3 Liquidity
A Current Ratio of 1.79 indicates that DR should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.79, DR belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
A Quick Ratio of 1.67 indicates that DR should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.67, DR belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.67 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 60.81% over the past year.
The Revenue for DR has decreased by -41.68% in the past year. This is quite bad
DR shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.59% yearly.
EPS 1Y (TTM)60.81%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%-23.33%
Revenue 1Y (TTM)-41.68%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-20.29%
3.2 Future
Based on estimates for the next years, DR will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.76% on average per year.
Based on estimates for the next years, DR will show a decrease in Revenue. The Revenue will decrease by -7.10% on average per year.
EPS Next Y34.23%
EPS Next 2Y14.43%
EPS Next 3Y10.76%
EPS Next 5YN/A
Revenue Next Year-20.98%
Revenue Next 2Y-10.85%
Revenue Next 3Y-7.1%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
DR is valuated reasonably with a Price/Earnings ratio of 9.74.
Based on the Price/Earnings ratio, DR is valued cheaper than 100.00% of the companies in the same industry.
DR's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.60.
A Price/Forward Earnings ratio of 9.42 indicates a reasonable valuation of DR.
100.00% of the companies in the same industry are more expensive than DR, based on the Price/Forward Earnings ratio.
DR's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.23.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.74 | ||
| Fwd PE | 9.42 |
4.2 Price Multiples
DR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. DR is cheaper than 100.00% of the companies in the same industry.
92.31% of the companies in the same industry are more expensive than DR, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.28 | ||
| EV/EBITDA | 4.6 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of DR may justify a higher PE ratio.
PEG (NY)0.28
PEG (5Y)N/A
EPS Next 2Y14.43%
EPS Next 3Y10.76%
5. Dividend
5.1 Amount
DR has a Yearly Dividend Yield of 2.35%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 1.27, DR pays a bit more dividend than its industry peers.
DR's Dividend Yield is comparable with the S&P500 average which is at 2.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.35% |
5.2 History
The dividend of DR decreases each year by -19.91%.
DR has been paying a dividend for at least 10 years, so it has a reliable track record.
DR has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)-19.91%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
DR pays out 6.72% of its income as dividend. This is a sustainable payout ratio.
DP6.72%
EPS Next 2Y14.43%
EPS Next 3Y10.76%
TSX:DR (12/31/2025, 7:00:00 PM)
15.87
+0.27 (+1.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.98%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap286.45M
Revenue(TTM)257.36M
Net Income(TTM)81.33M
Analysts42.22
Price Target16.58 (4.47%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.35% |
Yearly Dividend0.35
Dividend Growth(5Y)-19.91%
DP6.72%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.6%
Min EPS beat(2)-7.54%
Max EPS beat(2)6.33%
EPS beat(4)2
Avg EPS beat(4)3.38%
Min EPS beat(4)-24.98%
Max EPS beat(4)39.71%
EPS beat(8)3
Avg EPS beat(8)-25.78%
EPS beat(12)5
Avg EPS beat(12)32.86%
EPS beat(16)7
Avg EPS beat(16)-103.27%
Revenue beat(2)1
Avg Revenue beat(2)-1.3%
Min Revenue beat(2)-4.5%
Max Revenue beat(2)1.91%
Revenue beat(4)1
Avg Revenue beat(4)-6.39%
Min Revenue beat(4)-18.84%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-3.49%
Revenue beat(12)4
Avg Revenue beat(12)-2.43%
Revenue beat(16)5
Avg Revenue beat(16)-2.23%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.63%
EPS NY rev (1m)1.24%
EPS NY rev (3m)1.24%
Revenue NQ rev (1m)1.55%
Revenue NQ rev (3m)3.49%
Revenue NY rev (1m)1.27%
Revenue NY rev (3m)1.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.74 | ||
| Fwd PE | 9.42 | ||
| P/S | 0.81 | ||
| P/FCF | 4.28 | ||
| P/OCF | 3.94 | ||
| P/B | 2.43 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.6 |
EPS(TTM)1.63
EY10.27%
EPS(NY)1.69
Fwd EY10.62%
FCF(TTM)3.71
FCFY23.36%
OCF(TTM)4.03
OCFY25.38%
SpS19.52
BVpS6.53
TBVpS-0.86
PEG (NY)0.28
PEG (5Y)N/A
Graham Number15.48
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.18% | ||
| ROE | 94.43% | ||
| ROCE | 18.66% | ||
| ROIC | 15.42% | ||
| ROICexc | 19.71% | ||
| ROICexgc | 46.81% | ||
| OM | 15.59% | ||
| PM (TTM) | 31.6% | ||
| GM | 63.75% | ||
| FCFM | 18.99% |
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
ROICexc(3y)21.7%
ROICexc(5y)18.79%
ROICexgc(3y)53.59%
ROICexgc(5y)43.79%
ROCE(3y)19.81%
ROCE(5y)17.76%
ROICexgc growth 3Y35.06%
ROICexgc growth 5Y23.36%
ROICexc growth 3Y18.42%
ROICexc growth 5Y13.1%
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
F-Score6
Asset Turnover0.95
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.02 | ||
| Debt/FCF | 2.05 | ||
| Debt/EBITDA | 1.54 | ||
| Cap/Depr | 25.03% | ||
| Cap/Sales | 1.64% | ||
| Interest Coverage | 7.65 | ||
| Cash Conversion | 93.1% | ||
| Profit Quality | 60.09% | ||
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.67 | ||
| Altman-Z | 1.37 |
F-Score6
WACC8.63%
ROIC/WACC1.79
Cap/Depr(3y)47.79%
Cap/Depr(5y)40.36%
Cap/Sales(3y)2.81%
Cap/Sales(5y)2.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.81%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%-23.33%
EPS Next Y34.23%
EPS Next 2Y14.43%
EPS Next 3Y10.76%
EPS Next 5YN/A
Revenue 1Y (TTM)-41.68%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-20.29%
Revenue Next Year-20.98%
Revenue Next 2Y-10.85%
Revenue Next 3Y-7.1%
Revenue Next 5YN/A
EBIT growth 1Y-46.1%
EBIT growth 3Y-6.86%
EBIT growth 5Y-4.85%
EBIT Next Year3.98%
EBIT Next 3Y2.37%
EBIT Next 5YN/A
FCF growth 1Y-6.31%
FCF growth 3Y4.28%
FCF growth 5Y3.38%
OCF growth 1Y-24.65%
OCF growth 3Y3.26%
OCF growth 5Y1.55%
MEDICAL FACILITIES CORP / DR.CA FAQ
What is the fundamental rating for DR stock?
ChartMill assigns a fundamental rating of 7 / 10 to DR.CA.
Can you provide the valuation status for MEDICAL FACILITIES CORP?
ChartMill assigns a valuation rating of 9 / 10 to MEDICAL FACILITIES CORP (DR.CA). This can be considered as Undervalued.
Can you provide the profitability details for MEDICAL FACILITIES CORP?
MEDICAL FACILITIES CORP (DR.CA) has a profitability rating of 8 / 10.
What is the expected EPS growth for MEDICAL FACILITIES CORP (DR.CA) stock?
The Earnings per Share (EPS) of MEDICAL FACILITIES CORP (DR.CA) is expected to grow by 34.23% in the next year.
How sustainable is the dividend of MEDICAL FACILITIES CORP (DR.CA) stock?
The dividend rating of MEDICAL FACILITIES CORP (DR.CA) is 5 / 10 and the dividend payout ratio is 6.72%.